US pharmaceutical giant Pfizer has offered what it said would be its bid to acquire UK rival AstraZeneca, but its $119 billion proposal was turned down.
Reports say AstraZeneca rejected the bid just hours after it was introduced by Pfizer, despite Pfizer’s deadline for AstraZeneca to respond to the bid by May 26.
In a statement, AstraZeneca described the latest offer as a “minor improvement” from the last, which was made for $106 billion.
Despite the rejection, reports say Pfizer was not optimistic ahead of submitting its bid, and said it would not make a hostile takeover offer to AstraZeneca shareholders. In a statement, Pfizer CEO Ian Read said the company does not believe “that the AstraZeneca board is currently prepared to recommend a deal at a reasonable price.” The company added that it would remain open to further dialogue with the UK firm.
The merger would have created the world’s largest pharmaceutical company.’’
Full content: Yahoo News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI